Transcatheter Valve Repair in Heart Failure with Moderate to Severe Mitral Regurgitation
New England Journal of Medicine · 14.11.2024 · 391 (19) · 1799-1809
DOI: 10.1056/nejmoa2314328 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 14.11.2024. Verfasst von Stefan D Anker und 57 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Cardiology of German Heart Center Charité and the Institute of Health Center for Regenerative Therapies, German Center for Car…. Hauptthemen laut MEDLINE: Cardiac Catheterization, Heart Failure, Hospitalization, Mitral Valve. Die Arbeit wurde bisher 300-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Abbott Germany.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
BACKGROUND: Whether transcatheter mitral-valve repair improves outcomes in patients with heart failure and functional mitral regurgitation is uncertain. METHODS: We conducted a randomized, controlled trial involving patients with heart failure and moderate to severe functional mitral regurgitation from 30 sites in nine countries. The patients were assigned in a 1:1 ratio to either transcatheter mitral-valve repair and guideline-recommended medical therapy (device group) or medical therapy alone (control group). The three primary end points were the rate of the composite of first or recurrent hospitalization for heart failure or cardiovascular death during 24 months; the rate of first or recurrent hospitalization for heart failure during 24 months; and the change from baseline to 12 months in the score on the Kansas City Cardiomyopathy Questionnaire-Overall Summary (KCCQ-OS; scores range from 0 to 100, with higher scores indicating better health status). RESULTS: A total of 505 patients underwent randomization: 250 were assigned to the device group and 255 to the control group. At 24 months, the rate of first or recurrent hospitalization for heart failure or cardiovascular death was 37.0 events per 100 patient-years in the device group and 58.9 events per 100 patient-years in the control group (rate ratio, 0.64; 95% confidence interval [CI], 0.48 to 0.85; P = 0.002). The rate of first or recurrent hospitalization for heart failure was 26.9 events per 100 patient-years in the device group and 46.6 events per 100 patient-years in the control group (rate ratio, 0.59; 95% CI, 0.42 to 0.82; P = 0.002). The KCCQ-OS score increased by a mean (±SD) of 21.6±26.9 points in the device group and 8.0±24.5 points in the control group (mean difference, 10.9 points; 95% CI, 6.8 to 15.0; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- From the Department of Cardiology of German Heart Center Charité and the Institute of Health Center for Regenerative Therapies, German Center for Cardiovascular Research (DZHK) Partner Site Berlin, Charité Universitätsm…
ORCID-Profile: Tim Friede, Karl-Heinz Kuck, Aldo P Maggioni, Fausto J Pinto
Förderung
- Abbott Germany
Zitieren
APA
Anker, S. D., Friede, T., von Bardeleben, R. S., Butler, J., Khan, M. S., Diek, M., Heinrich, J., Geyer, M., Placzek, M., Ferrari, R., Abraham, W. T., Alfieri, O., Auricchio, A., Bayes-Genis, A., Cleland, J. G. F., Filippatos, G., Gustafsson, F., Haverkamp, W., Kelm, M., …, & RESHAPE-HF2 Investigators (2024). Transcatheter Valve Repair in Heart Failure with Moderate to Severe Mitral Regurgitation. New England Journal of Medicine, 391(19), 1799-1809. https://doi.org/10.1056/nejmoa2314328
Vancouver
Anker SD, Friede T, von Bardeleben RS, Butler J, Khan MS, Diek M, et al. Transcatheter Valve Repair in Heart Failure with Moderate to Severe Mitral Regurgitation. New England Journal of Medicine. 2024;391(19):1799-1809. doi:10.1056/nejmoa2314328
BibTeX
@article{Anker2024,
author = {Anker, Stefan D and Friede, Tim and von Bardeleben, Ralph-Stephan and Butler, Javed and Khan, Muhammad-Shahzeb and Diek, Monika and Heinrich, Jutta and Geyer, Martin and Placzek, Marius and Ferrari, Roberto and Abraham, William T and Alfieri, Ottavio and Auricchio, Angelo and Bayes-Genis, Antoni and Cleland, John G F and Filippatos, Gerasimos and Gustafsson, Finn and Haverkamp, Wilhelm and Kelm, Malte and Kuck, Karl-Heinz and Landmesser, Ulf and Maggioni, Aldo P and Metra, Marco and Ninios, Vlasis and Petrie, Mark C and Rassaf, Tienush and Ruschitzka, Frank and Schäfer, Ulrich and Schulze, P Christian and Spargias, Konstantinos and Vahanian, Alec and Zamorano, Jose Luis and Zeiher, Andreas and Karakas, Mahir and Koehler, Friedrich and Lainscak, Mitja and Öner, Alper and Mezilis, Nikolaos and Theofilogiannakos, Efstratios K and Ninios, Ilias and Chrissoheris, Michael and Kourkoveli, Panagiota and Papadopoulos, Konstantinos and Smolka, Grzegorz and Wojakowski, Wojciech and Reczuch, Krzysztof and Pinto, Fausto J and Wiewiórka, Łukasz and Kalarus, Zbigniew and Adamo, Marianna and Santiago-Vacas, Evelyn and Ruf, Tobias F and Gross, Michael and Tongers, Joern and Hasenfuss, Gerd and Schillinger, Wolfgang and Ponikowski, Piotr and RESHAPE-HF2 Investigators, RESHAPE-HF2 Investigators},
title = {Transcatheter Valve Repair in Heart Failure with Moderate to Severe Mitral Regurgitation},
journal = {New England Journal of Medicine},
year = {2024},
volume = {391},
number = {19},
pages = {1799--1809},
doi = {10.1056/nejmoa2314328}
}
EUVIMED